Leishmaniasis is a neglected tropical disease that can be deadly in its visceral form, and can also cause long-lasting illness after recovery. This week, the World Health Organization published major updates to its treatment guidance for countries in eastern Africa and South-East Asia.
The new recommendations aim for something patients immediately feel: shorter, safer, more practical care. WHO says the updated guidance includes alternative regimens for primary visceral leishmaniasis, new shorter and safer treatments for post-kala-azar dermal leishmaniasis (PKDL), and clearer relapse-management recommendations for South-East Asia.
One milestone is that WHO is recommending sodium stibogluconate (SSG)-free regimens for the first time. In eastern Africa, WHO recommends an oral medicine, miltefosine, combined with a paromomycin injection for both visceral leishmaniasis and PKDL.
WHO notes that the new visceral leishmaniasis treatment in eastern Africa can take 14 days and uses one fewer injection than the current 17-day regimen. For patients, that can mean fewer painful doses and less toxicity, without waiting for a future breakthrough drug to arrive.
Guideline updates are not a headline-grabbing kind of progress, but they shape care in real clinics. If adopted and implemented well, these changes could improve treatment for a large share of leishmaniasis patients in the regions covered.
(This story is about improved treatment guidance, not an eradication claim, and it does not change the fact that leishmaniasis remains a serious public health challenge.)
